Searchable abstracts of presentations at key conferences in endocrinology

ea0034p164 | Growth and development | SFEBES2014

Distinct gene expression is associated with epigenetic and growth-related network modules in relation to gender differences in the timing of the pubertal growth spurt

De Leonibus Chiara , Chatelain Pierre , Clayton Peter , Stevens Adam

Background: The return to active long bone growth in puberty is a distinctly human event1 and occurs ~2 years earlier in girls compared to boys. Evolutionarily conserved networks of genes are associated with the developmental phases of childhood in multiple tissues2, implying the existence of a genetic program that controls the pubertal return to growth.Objectives: To identify biological functions associated with gender and age-rela...

ea0033p67 | (1) | BSPED2013

Effect of latitude, summer daylight exposure and genetic background on growth response to recombinant human GH in GH deficient patients

De Leonibus Chiara , Chatelain Pierre , Clayton Peter , Stevens Adam

Introduction: Growth rate tends to be greater in children living at higher latitudes although the underlying mechanisms are unclear. The aim of this study was to compare height velocity (HV) in response to recombinant human GH (r-hGH) therapy in children with GH deficiency (GHD) living at different latitudes.Design: Pre-pubertal children with GHD (n=118) were enrolled from the PREDICT long-term follow-up prospective study (NCT00699855). Data wer...

ea0037ep120 | Steroids, development and paediatric endocrinology | ECE2015

Six-month interim safety and efficacy of different dose levels of transCon hGH administered once weekly versus standard daily human growth hormone replacement therapy in pre-pubertal children with growth hormone deficiency (GHD)

Chatelain Pierre , Malievsky Oleg , Radziuk Klaudziya , Elsedfy Heba Hassan , Mikhailova Evgenia , Beckert Michael

Background: TransCon hGH is a long-acting prodrug of recombinant human GH (hGH) that releases into the blood compartment fully active unmodified hGH. TransCon hGH was shown in two Phase 1 studies and a Phase 2 study in AGHD to be safe and well tolerated and inducing an IGF-I pharmacodynamic response within the normal range throughout the dosing period. This interim analysis consists of 25 patients completing all 6 months of treatment.Objectives: The obje...

ea0036oc3.7 | Oral Communications 3 | BSPED2014

Patterns of gene expression in pre-pubertal children are associated with the severity of their GH deficiency

Stevens Adam , De Leonibus Chiara , Chatelain Pierre , Murray Philip , Clayton Peter

Background: GH deficiency (GHD) has a spectrum of severity as characterised by GH stimulation tests; the cut-off level for GHD has been a long standing contentious issue. An independent biological correlate of severity would be valuable.Objectives: To identify patterns of gene expression (GE) that correlate with severity in GHD.Methods: Pre-pubertal children with GHD (n=72) were enrolled from the PREDICT study (NCT00256126...

ea0035s14.1 | Clinical outcome of medical intervention in Disorder of Sex Development (DSD) | ECE2014

dsd-LIFE: clinical European outcome study of disorders of sex development

Kohler Birgit , Arlt Wiebke , Bouvattier Claire , Chatelain Pierre , Grinten Hedi Claahsen van der , Cohen-Kettenis Peggy , Nordenstrom Anna , Pienkowski Catherine , Richter-Unruh Annette , Slowikowska-Hilczer Jolanta , Szarras-Capnik Maria , Reisch Nicole , Sultan Charles , Thyen Ute , Wiesemann Claudia

Disorders of sex development (DSD) include a conglomerate of rare conditions with discrepancy of the chromosomal, gonadal or phenotypic sex. Since the last 2 decades the genetic causes and the pathogenesis have been identified in many patients with DSD. Multidisciplinary clinical care as decision on the sex of rearing, genital surgery, hormone therapies and psychological support has a life-long impact on the affected persons. However, previous clinical outcome studies of DSD w...